Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 8, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone“), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options (“Options“) and 1,275,000 restricted share units (“RSUs“) under the Company’s equity incentive plan to certain officers and directors of the Company. Each Option is exercisable for one common share of the Company at a price of $0.28 per common share. 827,120 of the Options vest immediately and expire on May 8, 2032. 318,400 of the Options vest over a two-year period in various increments and expire between nine and ten years following the grant date. Each RSUs will vest for one common share of the Company on the date that is 12 months following the date of the grant.
The Company also announces the resignation of Eyal Flom from the board of directors of the Company for personal reasons, effective immediately. NurExone’s directors and management thank Mr. Flom for his service and wish him all the best with his future endeavors.